An investigation on behalf of investors of GenMark Diagnostics, Inc (NASDAQ:GNMK) shares over potential securities laws violations by GenMark Diagnostics and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of GenMark Diagnostics, Inc (NASDAQ:GNMK) concerning whether a series of statements by GenMark Diagnostics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Carlsbad, CA based GenMark Diagnostics, Inc. is a molecular diagnostics company that is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. GenMark Diagnostics, Inc reported that its annual Total Revenue rose from $39.41 million in 2015 to $49.27 million in 2016 and that its Net Loss increased from $42.20 million in 2015 to $50.60 million in 2016.

Shares of GenMark Diagnostics, Inc (NASDAQ:GNMK) rose from $4.65 per share in February 2016 to as high as $13.40 per share in March 2017.

On November 2, 2017, GenMark Diagnostics, Inc President and CEO Hany Massarany stated during an earnings conference call that revenue recognition for expected placements of ePlex was slowed by a longer than expected customer evaluation and validation process prior to implementation of ePlex in routine clinical use.